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Abstract: The year 2021 marks the 15th anniversary of the Paediatric Regulation (1901/2006/EC) in
Europe. The main aim of the study was to conduct a pre-post comparison on the annual off-label
prescription rates in the under-18 population in Spain and assess the potential influence of the
Paediatric Regulation adoption. An observational study in the paediatric population was performed.
Four cross-sectional annual periods, one before and the three latest periods after the adoption of
the Regulation, were compared. Prescriptions in the primary health care setting were sorted by age
group and drug and off-label status were determined. The number of off-label prescriptions issued
by paediatricians was over two million per year. Prior to the adoption of the Paediatric Regulation,
the off-label prescription rate was estimated at 7% of total prescriptions. Although the increase in
the off-label rate over the study periods was mild, it was statistically significant (OR: 1.045; 95% CI:
1.043–1.046; p < 0.05). One of the most vulnerable population groups was neonates and infants up to
1 year, in which the off-label prescription rates showed the highest increase during the post follow-up
period, which was statistically significant (OR: 4.270; 95% CI: 4.253–4.287; p < 0.05). The findings can
help raise awareness and advocate for the development and authorization of medicines for children
in the primary health care setting.
Keywords: off-label prescription; paediatrics; paediatric regulation; pharmaceutical products;
prescription drugs; primary health care
1. Introduction
The year 2021 marks the 15th anniversary of the Paediatric Regulation (1901/2006/EC)
in Europe [1]. The aim of this regulation was to ensure that appropriate studies in children
would be carried out in order to obtain the data necessary to support authorizing medicines
in the paediatric population. This regulation raised the need to establish similar standards
for paediatric medicines as for those used in adults, in terms of undergoing studies to ensure
that medicines are safe, effective and high quality to be used in the paediatric population.
Problems that commonly arise in current clinical practice, such as those related to the lack
of medicines suitably adapted to the needs of the paediatric population (i.e., incomplete or
insufficient dosage information that could be associated with an increased risk of adverse
drug events, under-dosage, etc.) should be avoided or, at least, minimized. The European
Medicines Agency (EMA) established procedures for paediatric investigation plans (PIPs),
the documents that should serve as a framework for the development and authorization of
medicinal products for children. Included in these PIPs are the requirements for adding a
new indication, pharmaceutical form, or route of administration for an already authorized
medicine covered by intellectual property rights [2].
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According to the European Federation of Pharmaceutical Industries and Associations
(EFPIA), medicine development in clinical trials takes an average of 12 years until approval
for use in patients [3]. Under this scenario, the outcomes of the PIPs in innovations could
have begun to be noted from year 2019. The latest update released by the European Com-
mission (August 2020) shows that the Paediatric Regulation (1901/2006/EC) has resulted
in an increase of almost 50% in clinical trials including children and in over 1000 PIPs
agreed. The number of paediatric products authorized also increased after the adoption of
the Regulation. By 2016, 101 paediatric medicines and 99 new paediatric indications had
been centrally authorized. In the same period, 10 new paediatric medicines received a na-
tional authorization and 57 new paediatric indications were added to nationally authorized
products [4].
In February 2017, the European Union (EU) published a study report on the off-label
use of medicinal products in the ten years following the adoption of the Paediatric Regula-
tion, which estimated that the regulation did not seem to have led to a lower prevalence
of off-label use in the EU, although the number of medicines developed for children had
increased during the ten-year period. The areas with the most progress were those in
which there was an overlap between the needs of paediatric patients and those of adults,
with far fewer achievements in rare diseases or diseases that mainly occur in children [5].
In 2018, a further report from the EMA highlighted the particular importance, for both
ethical and methodological reasons, of cross-border cooperation between regulators and
clinical research requirement compatibility for paediatric medicines [6]. The off-label
prescription which is justified by clinical practice is a frequent practice when therapeutic
alternatives are not available for the paediatric population group. This evidence-based
off-label prescription has been recently described by a novel joint policy statement in
Europe, with the purpose to offer guidance for health care professionals on when and how
to prescribe off-label medicines to children and to provide recommendations for future
European policy [7].
In Spain, in a two-year (2015 and 2016) cross-sectional study carried out for the
medicines prescribed in primary health care paediatric patients, off-label use of drugs
remained a public health concern especially for neonates and infants, who received the
greatest proportion of off-label drugs [8]. To our knowledge, no study has been undertaken
to determine the influence that the Paediatric Regulation adoption could have had on
the prevalence of off-label use of medicines at the primary health care level of a member
state. Thus, the main aims of the present study were to conduct a pre-post comparison
on the annual off-label prescription rates in the under-18 population in Spain and assess
the potential influence of the latest Paediatric Regulation (1901/2006/EC) adoption. In
addition, a brief description of the legal framework in Spain for each study period was
carried out, in relation to prescription in medicines on primary health care.
2. Materials and Methods
2.1. Study Design and Setting
An observational study of off-label prescription in population under 18 years of age
at primary health care in Spain. Four annual periods were compared: one prior to the
publication of the Paediatric Regulation (1901/2006/EC) (October 2004–September 2005)
and three corresponding to the latest available periods following the adoption of the
Regulation (October 2017–September 2018, October 2018–September 2019 and October
2019–September 2020).
General practitioners (GPs), paediatricians, auxiliary nurses, social workers, dentists
and administrative staff are the backbone of the primary health care workforce in Spain [9].
According to the latest data available (2018), the Spanish National Health System has
143,995 health professionals, of which 35,486 (28,980 GPs and 6506 paediatricians) work in
primary health care, which represents a rate of 0.8 per 1000 inhabitants [10].
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2.2. Population and Eligibility Criteria
The target population is prescriptions for children and adolescents between the ages
of 0 and 17. According to the official national data, the population between 0 and 17 years
old in Spain increased from 7.6 million in January 2005 to 8.3 million in January 2020. This
population group accounted for 18% of total population in the country for the four study
periods [11].
Inclusion criteria: All prescriptions issued by primary care paediatricians, targeting
all inhabitants aged 0–17 years old treated as outpatients in primary health care.
Exclusion criteria: All prescriptions issued in hospitals (inpatients) and by primary
health care professionals other than paediatricians, such as GPs, nurses and other health
professionals.
2.3. Data Sources
Study data collection included the prescription records from a private database (com-
plete national scope) sorted by age group and drug (brand name, active ingredient, strength,
package and dosage form) [12]. The primary source to determine off-label status was the
General Pharmaceutical Council of Spain database (BotPlus 2.0) [13], which included an
updated list of medicines which are not authorized for use in those under the age of 18.
This database, which is available online, allows one to design and download a file with the
medicines selected under this condition. The Official State Gazette of Spain (BOE) was also
consulted online as a regulation source.
2.4. Variables
Variables collected were quantitative: demographic (age group) and resource use
(number and percentage of prescriptions: total, off-label, by brand name, by active ingredient
and by age group) and also qualitative: active ingredients and pharmacological subgroups
(name and Anatomical Therapeutic Chemical Classification System (ATC) code) [14].
A prescription is the official form used to prescribe a medicine. According to the
Spanish regulation, a single prescription could be used to prescribe several packages of the
same medicine in specific situations (i.e., insulins and some systemic antibiotics).
Four age groups were defined: <1 year old (full-term neonates and infants), 1–<2 years
old (toddlers), 2–11 years old (children) and 12–<18 years old (adolescents) [15].
In the present study, off-label drugs were defined as those that were not authorized
for an age group according to the information in the BotPlus 2.0 database. Otherwise,
they were on-label. For brand name prescriptions, the match was applied according to
brand name in BotPlus 2.0, and in the case of active ingredient prescriptions, the match was
applied according to active ingredient in BotPlus 2.0; in the latter, if the active ingredient
had been included either in a branded product or in a generic one, it was considered as a
possible off-label prescription and then counted.
2.5. Data Analysis
A descriptive analysis was carried out. Total number of prescriptions were studied
according to labelling and drug characterization. Quantitative variables were published
as totals and percentages. Percentages were also calculated for the characterization of the
most prescribed off-label drugs.
Off-label assessment was carried out by two researchers independently; conflicts
were resolved through discussion and consensus or consultation with a third reviewer.
According to the BotPlus 2.0 database and the information included for off-label use in the
under-18 population, some inconsistencies were detected, which led to some assumptions
that were made during data analysis to address them (Table 1).
A statistical analysis of the data was also performed. The Odds Ratio (OR) of the
number of off-label prescriptions in relation to the total number of prescriptions was
calculated with 95% Confidence Intervals (CI). Also, the number of off-label prescriptions
by brand name or active ingredient in relation to the total number of off-label prescriptions
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was considered. The year prior to the legislative change (October 2004–September 2005)
was compared to the aggregate data of the three study periods after the legislative change
(from October 2017 to September 2020).
Table 1. Definition of inconsistencies that were identified in the BotPlus 2.0 database according to off-label indication in the
under-18 population.
Inconsistency Description Examples Assumption/Decision
Medicines with the same active
ingredient, similar formulation and
administration route, where low doses
were classified as off-label but not high
doses.
Pantoprazole and Omeprazole 20 mg
(tablets or capsules) were defined as
off-label in the under-18 population but
not 40 mg.
Pantoprazole and Omeprazole 20 mg
(tablets or capsules) were considered
off-label in the under-18 population.
Paracetamol 500 mg effervescent tablets
and 1 g tablets (effervescent or not) were
defined as off-label in the under-18
population, but not 500 mg tablets or
capsules.
Paracetamol 500 mg tablets and capsules
were considered off-label in the under-18
population.
Topical medicines with the same active
ingredient, same dose or concentration
and administration route, where some
formulations were classified as off-label,
but others were not depending on the
formulation.
Similar formulations:
Ketoconazole cream was defined as
off-label in the under-18 population but
not the gel, which is also a semi-solid.
Both were formulated with the same
concentration (2%; 20 mg/g).
Both Ketoconazole cream and
Ketoconazole gel were considered
off-label in the under-18 population.
Topical medicines with the same active
ingredient, different dose or
concentration and same administration
route, where some formulations were
classified as off-label, but others were not
depending on the formulation.
Different formulations:
Centella asiatica herba in combination with
antibiotics formulated as powder (solid)
was defined as off-label in the under-18
population but not the ointment
(semi-solid). Both were formulated with a
different concentration (powder, 1%;
ointment, 2%).
Only Centella asiatica herba powder was
considered off-label in the under-18
population.
Topical medicines with the same active
ingredient, same dose or concentration
and administration route, where some
formulations were classified as off-label,
but others were not depending on
whether they were brands or generics.
In the case of Ciclopirox, the variability in
off-label designation depended on the
brand name, ranging from nail lacquer to
shampoo, topical solution and cream.
For Ciclopirox brand names, the off-label
designation was assessed following
BotPlus 2.0 criteria brand by brand in the
under-18 population.
In the case of Ciclopirox generics, all
formulations have been assessed as
potentially off-label in the under-18
population.
Medicines with many generics in the
market, where some were classified as
off-label, but others were not.
Many generics of Paracetamol 1 g and
500 mg tablets.
Due to the high number of cases
identified under this condition, all
Paracetamol 1 g and 500 mg prescriptions
by active ingredient were assessed as
potentially off-label in the under-18
population.
3. Results
3.1. Total Prescriptions and Off-Label Rates in the Under-18 Population: Global Results
Overall, more than 150 million prescriptions were assessed for off-label use in the
under-18 population during the four study periods (Table 2). Prescriptions by brand name
were the most commonly issued by paediatricians, accounting for more than 70% of total
prescriptions in all study periods.
The number of off-label prescriptions issued by paediatricians in the target population
were estimated to be higher than 2 million per year (Table 2). Prior to the adoption of the
Paediatric Regulation (1901/2006/EC), the off-label prescription rate was estimated at 7%
of total prescriptions (3% of prescriptions by brand name and 4% of prescriptions by active
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ingredient). Although the 7% off-label rate remained almost unchanged during all study
periods, off-label brand name prescriptions increased to 6% and those by active ingredient
decreased to 2% in the latest study period (October 2019–September 2020).
Table 2. Number of prescriptions and off-label rates per study period in the under-18 population.


























































* Percentage calculated over total prescriptions in the under-18 population; † Percentage calculated over prescriptions by brand name or
active ingredient in the under-18 population. Abbreviations: MAT, moving annual total (12-month period).
After a pre-post comparison, the increase in off-label prescriptions was mild (OR:
1.045) but showed statistical significance (95% CI: 1.043–1.046; p < 0.05) after the Paediatric
Regulation (1901/2006/EC) [1] adoption.
Regarding off-label prescriptions by brand name or active ingredient, a significant
increase was observed in brand name prescriptions (OR: 2.431; 95% CI: 2.426–2.436; p < 0.05)
and a subsequent decrease in off-label prescriptions by active ingredient (OR: 0.171; 95%
CI: 0.171–0.172; p < 0.05).
An overview of the legal framework in Spain for each study period is included in
Table 3. Basically, it describes the general rules regarding the prescription of medicines
in the outpatient setting. Prioritization of prescriptions by active ingredient in Spain was
introduced starting with Royal Decree-Law 16/2012 [16], which contributed to the former
Royal Legislative Decree 1/2015, the one that was in force during the final three study
periods (after the Paediatric Regulation (1901/2006/EC) publication).
Table 3. Local regulation and general rules regarding the prescription of medicinal products during each period of the
project.
Period (MAT) Regulation in Force Comments
October
2004–September 2005 Law 25/1990 [17]
Aim: The primary objective is to contribute to the provision of safe, effective and quality
medicines, properly identified and with appropriate information.






Aim: To guarantee the quality of all benefits being provided by the Spanish National Health
System, ensuring better protections for the rational use of medicines and that access to medicines
is done through a more effective system with tighter safety controls.
Prescription of medicines: The general rule is to prescribe by active ingredient whereby the least
expensive medicinal product within its homogeneous group * will be supplied and, if the prices
are the same, the appropriate generic or biosimilar medicinal product will be supplied.
- In acute conditions and the first prescription for chronic conditions, prescriptions will,
generally, be issued by active ingredient.
- Brand names are allowed to be prescribed, subject to the principle of greater efficiency for
the system or where the medicinal products concerned are regarded as being
non-substitutable.
- If the price of a medicinal product prescribed by brand name is higher than the lowest
priced product in its homogeneous group, the pharmacist must substitute the prescribed
product with the lower priced product and, if the prices are the same, must supply the





* Spanish regulation groups outpatient medicines which are reimbursed by the National Health Service into “homogeneous groups”. Each
homogeneous group is formed by pharmaceuticals with the same active ingredient (regardless of being branded or generic), dose, content,
pharmaceutical form and route of administration, which can be interchangeable. The lowest price of each homogeneous group is the
maximum price paid by the National Health Service. The lowest price is updated each month. Abbreviations: MAT, moving annual total
(12-month period).
Pharmaceutics 2021, 13, 588 6 of 12
The most relevant therapeutic groups and the active ingredients that accounted for
the highest number of off-label prescriptions (<55% and >70%, respectively) were analyzed
(Tables 4 and 5).
Table 4. Number of off-label prescriptions for the top 10 most-prescribed active ingredients per study
period in the under-18 population.






Dexamethasone and anti-infectives 129,455 (4%)
Budesonide 125,352 (4%)














Methylprednisolone aceponate 84,551 (4%)









Dexamethasone and anti-infectives 72,970 (3%)
Acetylcysteine 63,630 (2%)











Methylprednisolone aceponate 78,827 (3%)
Ciclopirox 62,718 (2%)
Dexamethasone and anti-infectives 60,289 (2%)
Silicones 59,611 (2%)
* Percentage calculated over total off-label prescriptions in the population under the age of 18.
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Table 5. Number of off-label prescriptions in the top 5 most-prescribed pharmacological subgroups per study period in the
under-18 population.
Period Pharmacological Subgroups (ATC Code and Description) Off-Label Prescriptions(Total), n (%) *
October
2004–September 2005
M01A Anti-inflammatory and antirheumatic products, non-steroids 1,121,520 (38%)
N02B Other analgesics and antipyretics 760,808 (26%)
A03A Drugs for functional gastrointestinal disorders 130,981 (4%)
S03C Corticosteroids and anti-infectives in combination 129,455 (4%)
R01A Decongestants and other nasal preparations for topical use 123,399 (4%)
October
2017–September 2018
A11C Vitamin A and D, incl, combinations of the two 505,517 (24%)
N02B Other analgesics and antipyretics 242,700 (12%)
A02B Drugs for peptic ulcer and gastro-esophageal reflux disease 159,644 (8%)
M01A Anti-inflammatory and antirheumatic products, non-steroids 151,669 (7%)
A07E Intestinal anti-inflammatory agents 148,852 (7%)
October
2018–September 2019
A11C Vitamin A and D, incl. combinations of the two 646,194 (24%)
R03D Other systemic drugs for obstructive airway diseases 579,251 (22%)
N02B Other analgesics and antipyretics 224,193 (8%)
A02B Drugs for peptic ulcer and gastro-esophageal reflux disease 127,022 (5%)
R01A Decongestants and other nasal preparations for topical use 119,031 (4%)
October
2019–September 2020
A11C Vitamin A and D, incl. combinations of the two 674,105 (26%)
R03D Other systemic drugs for obstructive airway diseases 360,325 (14%)
R06A Antihistamines for systemic use 199,125 (8%)
N02B Other analgesics and antipyretics 197,504 (8%)
A02B Drugs for peptic ulcer and gastro-esophageal reflux disease 137,866 (5%)
* Percentage calculated over total off-label prescriptions in the population under the age of 18. Abbreviations: ATC, Anatomical Therapeutic
Chemical Classification System.
Focusing specially on prescriptions by brand name, very few examples were identified
of new drugs authorized from 2016 on, i.e., ten years after the publication of the Paediatric
Regulation (1901/2006/EC).
During the three last study periods, an average of 356 different brand names were
prescribed yearly in the under-18 population. Of these, only five were authorized after the
year 2016 and were mostly indicated for dermatological conditions (n = 3). However, only
one of the active ingredients was a real innovation (i.e., ozenoxacin, a topical antibiotic for
the treatment of impetigo), as the others were additional new brands for existing medicines
(i.e., ciclopirox, mometasone, prednisolone and combinations of calcipotriol).
3.2. Total Prescriptions and Off-Label Rates in the Under-18 Population: Results by Age Group
The age group that accounted for more than 60% of total prescriptions in all study
periods was children between 2 and 11 years old, followed by neonates and infants
(<1 year old), who accounted for 14–16% of all prescriptions in the under-18 population
(Table 6).
The only age group that showed an increase in the percentage of off-label prescriptions
after the Paediatric Regulation (1901/2006/EC) adoption was the under-1 population,
whose rate increased 325%, from 4% (October 2004–September 2005) to 17% (October 2019–
September 2020) over total prescriptions in the under-1 population. Likewise, the off-label
prescription rate was initially estimated at 10% of total prescriptions in the population
under 18, but it has been increasing up to 34% in the latest period (a 240% increase)
(Table 6).
According to the statistical analysis, two opposite effects were observed. On the one
hand, there was a significant increase in the number of off-label prescriptions in the under-1
population (OR: 4.270; 95% CI: 4.253–4.287; p < 0.05) and a mild increase in the group of
children between 1 and <2 years old (OR: 1.045; 95% CI: 1.039–1.051; p < 0.05). On the other
hand, a downward trend was observed in the population aged 2 to 11 years (OR: 0.630;
95% CI: 0.629–0.631; p < 0.05) and 12 to <18 years (OR: 0.752; 95% CI: 0.750–0.755; p < 0.05).
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Table 6. Number of prescriptions and off-label rates per study period in the under-18 population by age group.
Period (MAT)
<1 Year Old 1–<2 Years Old 2–11 Years Old 12–<18 Years Old
Prescriptions































































































* Percentage calculated over total prescriptions in the population under the age of 18; ** Percentage calculated over total prescriptions in
the population group; § Percentage calculated over total off-label prescriptions in the population under the age of 18. Abbreviations: MAT,
moving annual total (12-month period).
4. Discussion
4.1. Total Prescriptions and Off-Label Rates in the Under-18 Population: Global Results
Prescription of medicines by brand name was the most common practice among
paediatricians (i.e., 85%, 71%, 73% and 73% respectively, depending on the study period).
Before July 2006, the local regulation in force had not started protecting generic drugs
and promoting prescription by active ingredient, which could explain the higher rate
of prescription by brand name during this period (85%). This trend slightly decreased
in the following periods, which could be influenced by the new regulation or could be
coincidental.
The off-label prescription rate variation was mild in pre-post comparison, as it was
between 6% and 8%, but significant (p < 0.05), which indicated that the Paediatric Regu-
lation (1901/2006/EC) [1] adoption did not have any impact in this regard for primary
care paediatricians. Conversely to total prescriptions, off-label prescriptions by brand
name increased throughout the study periods (from 3% to 6% of total prescriptions in
the under-18 population). Consequently, the risk of off-label prescription did not appear
to be influenced by either the protectionist regulation endorsing prescription by active
ingredient in Spain [18] or by the adoption of the Paediatric Regulation (1901/2006/EC) [1]
in the EU.
Regarding the extent of off-label use in EU, the systematic literature review undertaken
by Weda et al. (2017) [5] showed a wide range of off-label rates (2–100%) in the outpatient
setting for children (≤18 years) after analyzing 40 studies. In addition, wide variation
between countries was observed and no clear patterns were identified. Under this scenario,
the results from our study would be positive, being on the lower end of the range (<10%).
The only study from Spain that was included in this publication, Ruiz-Antorán et al.
(2013) [19], pointed to a prevalence of off-label use of 33.2%.
A recent systematic literature review of off-label medication use in the population
<18 years identified 31 studies (in a mix of inpatient and outpatient settings), with off-
label prescription rates from 3.2% to 95% [20]. However, most of the studies that aimed
to determine the prevalence of off-label use in Spain and drug characterization in the
population under 18 were mainly focused on at hospital settings [21,22] and could not be
compared to those presented here.
According to the results of the 2012–2013 paediatric national survey of off-label drug
use in children in Spain (OL-PED) [23], a significant percentage of paediatricians went
on prescribing medications in their daily clinical practice without knowing whether the
drug was indicated in children or for certain age groups. 673 responses were received.
75% of paediatricians knew the meaning of off-label use, 61% of them prescribed off-
label medicines and just a small percentage (22% of them) wrote it down in the patient’s
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medical record as recommended by the Spanish legislation [24]. Although this survey
was carried out after the adoption of the Paediatric Regulation (1901/2006/EC) [1], the
authors indicated a need to adopt measures to raise awareness of the use of off-label (e.g.,
spontaneous notifications). To our knowledge, no further follow-up has been published on
this survey.
In the EU study in 2017, the most common therapeutic areas in which off-label use
in children was identified were cardiovascular diseases (e.g., antihypertensives), infec-
tious diseases (e.g., antibacterial drugs), central nervous system (e.g., analgesic agents),
respiratory system (e.g., asthma medicines) and alimentary tract and metabolism drugs
(e.g., reflux medicines). In the case of the present study, those pharmacological subgroups
with the highest number of off-label prescriptions were focused on the alimentary tract
and metabolism (e.g., peptic ulcer and gastro-esophageal reflux disease; intestinal anti-
inflammatory agents; vitamin A and D), analgesics (e.g., other analgesics and antipyretics),
the respiratory system (e.g., decongestants and other nasal preparations for topical use;
antihistamines for systemic use; other systemic drugs for obstructive airway diseases),
the musculo-skeletal system (e.g., anti-inflammatory and antirheumatic products, non-
steroids), and the sensory organs (e.g., corticosteroids and anti-infectives in combination).
More than 70% of off-label prescriptions for outpatients in Spain consisted of active
ingredients that had been in the market for decades (e.g., ibuprofen, paracetamol, ketocona-
zole, domperidone, colecalciferol or budesonide), which excluded them from being in the
primary scope of the latest Paediatric Regulation (1901/2006/EC) in Europe. Consequently,
the changes introduced by this Regulation in terms of new product development and
authorization could have had little or no impact in off-label prescription rates throughout
the study period. This scenario could also reveal a pattern: Spanish paediatricians in the
primary health care setting are not early adopters of innovation. This pattern could be
justified by multiple reasons (i.e., high price of innovations, uncertainty over the lack of
long-term data about effectiveness and safety), although they are out of the scope of the
present study. What is clear is that regardless of being off-label medicines according to
the SmPC, paediatricians in the primary health care setting in Spain seem to rely strongly
on the existing post-authorization clinical evidence to prescribe in the population under
the age of 18. Other source of additional information for prescription could be the Ameri-
can label authorized by the Food and Drug Administration (FDA), since sometimes the
same medicines have different indications depending on the geographical location and/or
medicines agency involved, thereby leaving the door open for off-label use.
4.2. Total Prescriptions and Off-Label Rates in the Under-18 Population: Results by Age Group
Patients under 1 year of age are the most vulnerable segment of the population
with regards to adverse drug events in case of off-label drug use [5,23]. Following this
statement, it should be noted that the results of the present study pointed out that off-label
prescriptions increased significantly in the population under 2 after the adoption of the
Paediatric Regulation (1901/2006/EC). Additionally, the recent systematic literature review
from Almeida et al. (2020) [25] found that the highest proportion of unlicensed prescription
in primary health care setting was in children under 2 years of age.
This increase was dramatically higher in those under 1 year of age, which raises
a red flag regarding the management of this population group, increasing its risk and
vulnerability. Despite the fact that the total number of prescriptions issued by paediatricians
for this age group decreased throughout the study periods, the off-label prescription rate
greatly increased. Considering the total prescriptions in this age group, the off-label rate
increased fourfold throughout the first and last study periods, specifically from 4% to 17%.
The difficulty of dose determination and new drug development programs for its use in
neonates is of utmost importance. Some diseases are unique to neonates, but others could be
similar (or not) to other population groups, which adds complexity to this end. In addition,
several factors should be considered for specific drug dosing approaches, as maturational
pharmacokinetics and body size, which play a unique role in this subpopulation group [26].
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Although off-label use risks compromising patients’ safety, many experiences of use in
new indications and age groups are supported by the literature and by real-world evidence.
Formally, the Summary of Product Characteristics (SmPC) is the legal document approved
as part of the marketing authorization of each medicine which is the primary source to
determine off-label prescription. It is based on pivotal randomized clinical trials and its
modification requires additional and time-consuming procedures of evaluation with the
regulatory bodies, based on new highly controlled randomized clinical trials.
However, there are alternative sources of robust information, for instance, the British
National Formulary, Pediamécum (a Spanish documentary database of active substances
used in Paediatrics) or DailyMed in the United States. These databases collect and validate
updated clinical practice, such as the off-label use of medicines. Most health professionals
rely on the information gathered in these databases and use it in their current clinical
practice. This situation exposes the gap that exists between real-world evidence or real
clinical practice and the regulatory basis of medicines use, which may lead to the observed
impairment between the results of this study and the current legal framework.
Finally, the fact that during the three last study periods, only one of the active in-
gredients was a real innovation (ozenoxacin) reflects that very few new medications are
finally authorized and marketed to be prescribed by primary care paediatricians. Drugs of
most interest in this study (e.g., ibuprofen, paracetamol, colecalciferol, budesonide, etc.),
which are included in Table 4, have been in the market for decades, which excludes them
of being in the primary scope of the latest Paediatric Regulation (1901/2006/EC) in Europe,
focused on new product development and authorization. In this context, maybe research
and development of medicines adapted to paediatric needs should not only comprise
innovations but also mature products in future initiatives. On the other side, the access of
innovations could also be limited for certain innovations in primary health care in Spain
(e.g., highest prices than the standard of care, uncertainty in effectiveness), which would
slow down its introduction in clinical practice [5].
4.3. Limitations of the Study
This study has some limitations that could lead to an estimation bias of off-label use
(low incidence). First, this study was focused on the off-label use of authorized medicines
and did not include medical devices, compounded formulas, cosmetics, food supplements
and medicinal plants. Second, only prescriptions issued by paediatricians in primary health
care were considered; prescriptions from another medical specialties or those derived from
hospitalizations were excluded. Third, non-prescription medicines were not taken into
account (i.e., self-medication). Fourth, as the data analyzed was not linked to medical
records, it was not possible to assess the indication, the dose or if the off-label use was
justified by the paediatricians. Fifth, results show potential off-label use from prescriptions,
as dispensation data was not provided by the database used. Sixth, the information about
off-label drugs in the used database does not contain a breakdown by ages, meaning that it
considers the under-18 population as a whole; subsequent analysis by SmPC information
will be needed as a further step to refine results by age. Regretfully it is not possible to
do this automatically, so it is not feasible to analyze case by case for such a huge number
of prescriptions analyzed (>150 million). Finally, our primary source of information lacks
accurate information about total prescriptions in Spain for the period prior to 2005, which
prevented increasing the sample of pre-follow-up periods and upgrading the statistical
analysis. Nevertheless, the highest number of prescriptions assessed for off-label use,
accounting for the total paediatric population (0–17 years) in Spain for four years, adds
value to this project and the results disclosed previously.
5. Conclusions
This study did not find a decrease of the annual off-label prescription rate in the
primary health care setting of the Spanish paediatric population, even though the latest
Paediatric Regulation (1901/2006/EC) publication, and more than 10 years after its adop-
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tion. The most likely explanation for this gap is the scarce prescription of innovations
in primary health care setting, which could benefit from the initiatives introduced by
this regulation. Conversely, most prescriptions (>70%) issued for the paediatric outpa-
tients included in the study consisted of active ingredients that had been in the market for
decades and consequently were not under the scope of this regulation in terms of paediatric
development for a safer use of medicines in the population under 18.
It should be noted that neonates and infants (<1 year old) accounted for 14–16%
of all prescriptions in the under-18 population and together with those between 1 and
<2 years old were the only age groups that also showed a relevant increase in the off-
label prescription rate. The vulnerability of these age groups and the global findings of
the present project can help raise awareness and advocate for the development of safer
medicines for children. Future initiatives and legislative tools should encourage research
and development of paediatric medicines focused on the areas of highest unmet need, also
in the primary healthcare setting, promoting the international cooperation of regulatory
bodies across the globe and speeding up the time to market.
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